CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Medical Isotopes and Alternatives for Diagnostic Imaging

Last updated: April 29, 2011
Product Line: Optimal Use
Result type: Report

Want to Know More About Medical Isotopes?

Health Canada: Frequently Asked Questions

The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a multifaceted project to support greater efficiency and effectiveness in the health system management of the medical isotope technetium-99m (99mTc).

In light of recent global supply disruption of 99mTc, CADTH will be developing guidance on how to prioritize the use of this medical isotope. The evaluation will also assess how 99mTc compares with other medical imaging options, such as magnetic resonance imaging (MRI) or other medical isotopes.  

The goal of the project is to provide Canadian health care decision-makers with evidence-based guidance on policies, protocols, and standards related to 99mTc. This will help support optimal access to appropriate medical imaging for Canadians.